Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EPS (Weighted Average and Diluted) (2021 - 2025)

Rani Therapeutics Holdings (RANI) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.12 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 50.0% year-over-year to -$0.12; the TTM value through Sep 2025 reached -$0.79, up 56.11%, while the annual FY2024 figure was -$1.05, 21.05% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.12 in Q3 2025 per RANI's latest filing, up from -$0.18 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.37 in Q2 2023 and bottomed at -$681.12 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$40.36, with a median of -$0.26 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 99.68% in 2022, then crashed 213.79% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$681.12 in 2021, then skyrocketed by 99.68% to -$2.21 in 2022, then soared by 54.3% to -$1.01 in 2023, then soared by 73.27% to -$0.27 in 2024, then soared by 55.56% to -$0.12 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.12 in Q3 2025, -$0.18 in Q2 2025, and -$0.22 in Q1 2025.